DIAGNOSTIC TECHNIQUE FOR METABOLIC SYNDROME IN SCHIZOPHRENIC PATIENTS RECEIVING NEUROLEPTIC THERAPY Russian patent published in 2020 - IPC A61B5/107 G01N33/92 G01N33/66 G01N33/68 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to psychiatry. Presence of abdominal obesity - waist circumference (WC) more than 80 cm in females and more than 94 cm in males, blood pressure (BP) 130/85 mm Hg and more, concentration of triglycerides (TG) more than 1.7 mmol/l, concentration of high-density lipoprotein cholesterol (HDL-C) less than 1.03 mmol/l in males and less than 1.29 mmol/l in females, glucose concentration in blood plasma of 5.6 mmol/l and more. Additionally, concentrations of apolipoprotein C2 (AroC2) and apolipoprotein C3 (AroC3) are determined. If AroC2 concentration is more than 25 mcg/dl and AroC3 is more than 45 mcg / dl, metabolic syndrome is diagnosed. Method provides higher diagnostic accuracy of metabolic syndrome in patients with schizophrenia receiving neuroleptic therapy by determining WC, BP, TG, HDL-C and glucose in patients with schizophrenia and additional determination of AroC2 and AroC3 in the patients upon admission to the clinic.

EFFECT: invention can be used for diagnosing metabolic syndrome in schizophrenic patients receiving neuroleptic therapy.

1 cl, 1 tbl, 1 ex